Personalized cancer treatment: matching drugs to tumor DNA may delay disease worsening
NCT ID NCT07346209
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether drugs chosen to match specific DNA mutations in a patient's tumor can delay cancer worsening better than standard treatments. About 280 adults with metastatic or unresectable solid cancers will be randomly assigned to receive either DNA-matched therapy or standard care. Participants will visit the clinic every two months for checkups and imaging to track their progress.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Molecularly matched therapy (drugs chosen based on tumor DNA mutations)
- What this could lead to
- If successful, this could show that personalized, DNA-matched drugs delay cancer worsening better than standard treatments.
- What could go wrong
- This is a Phase 2 trial, so results are early and may not confirm benefit. The approach depends on finding actionable mutations, which may not be possible for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of California, San Diego
La Jolla, California, 92093, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tissue analysis may guide personalized cancer therapy
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Blood test vs. scalpel: could liquid biopsy replace tissue biopsies for cancer monitoring?
- Can a new nucleotide analogue boost cancer treatment?
- Zapping resistant tumors with precision radiation may extend the life of current cancer therapy
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?